$250 | Single User
$500 | Site License
$750 | Enterprise License

Multiple Myeloma Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile
[Report Updated: 17-10-2017]

Published by Global Data: 17 Oct 2017 | 139924 | In Stock
Related Topics: Healthcare , Multiple Myeloma , Myeloma

Introduction

Summary

Multiple Myeloma Research Foundation (MMRF) is a non-profit foundation that develops advanced multiple myeloma treatments. The foundation provides end-to-end solutions for drug discovery and development targeting multiple myeloma. It provides clinical trails such as molecularly targeted therapies, immune therapies and noval therapies. MMRF's offers educational programs for people suffering from myeloma. The foundation provides funded grants for academic researchers and coMMpass study. It partners with bio-technology and pharmaceutical, academia, and the cancer community industries. MMRF is headquartered in Norwalk, Connecticut, the US.

Multiple Myeloma Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
for Multiple Myeloma Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 17-10-2017]

  • Table of Contents

    Table of Contents 3

    List of Tables 4

    List of Figures 4

    Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

    Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

    Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

    Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

    Multiple Myeloma Research Foundation, Medical Devices Deals, 2011 to YTD 2017 9

    Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

    Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deal Details 11

    Partnerships 11

    Multiple Myeloma Research Foundation Enters into Agreement with Memorial Sloan Kettering Cancer Center 11

    Multiple Myeloma Research Foundation Partners with University of Torino and Adaptive Biotech 12

    Inflection Biosciences Enters into Agreement with Multiple Myeloma Research Foundation 13

    GNS Healthcare Partners with Multiple Myeloma Research Foundation 14

    Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 15

    Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With Astellas Pharma 16

    Multiple Myeloma Research Foundation Enters Into Collaboration With Synta Pharma For Ganetespib 17

    Multiple Myeloma Research Foundation - Key Competitors 19

    Multiple Myeloma Research Foundation - Key Employees 20

    Multiple Myeloma Research Foundation - Locations And Subsidiaries 21

    Head Office 21

    Recent Developments 22

    Other Significant Developments 22

    Jun 29, 2017: Multiple Myeloma Research Foundation (MMRF) Announces Million Investment in Immunotherapy Initiative 22

    Appendix 23

    Methodology 23

    About GlobalData 23

    Contact Us 23

    Disclaimer 23

List Of Tables
in Multiple Myeloma Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 17-10-2017]

List of Tables

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Key Facts 2

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Multiple Myeloma Research Foundation, Deals By Therapy Area, 2011 to YTD 2017 8

Multiple Myeloma Research Foundation, Medical Devices Deals, 2011 to YTD 2017 9

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Multiple Myeloma Research Foundation Enters into Agreement with Memorial Sloan Kettering Cancer Center 11

Multiple Myeloma Research Foundation Partners with University of Torino and Adaptive Biotech 12

Inflection Biosciences Enters into Agreement with Multiple Myeloma Research Foundation 13

GNS Healthcare Partners with Multiple Myeloma Research Foundation 14

Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 15

Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With Astellas Pharma 16

Multiple Myeloma Research Foundation Enters Into Collaboration With Synta Pharma For Ganetespib 17

Multiple Myeloma Research Foundation, Key Competitors 19

Multiple Myeloma Research Foundation, Key Employees 20

List Of Figures, Charts and Diagrams
in Multiple Myeloma Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 17-10-2017]

List of Figures

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Multiple Myeloma Research Foundation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Multiple Myeloma Research Foundation, Medical Devices Deals, 2011 to YTD 2017 9

Additional Details

Publisher

Global Data

Publisher Information

Reference

139924 |

Number of Pages

23

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

Multiple Myeloma Research Foundation - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 17-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...